it is likely that Halozyme will license the ex-us (outside usa) rights for Pegph20 to Roche for a large upfront sum (at least half a billion) + milestones (possibly another half billion) for one or two solid tumor indications and keep US rights and other cancer indications for itself.
We have seen this collaboration model many times before with successful phase 2 results with blockbuster candidates like pegph20
News 
Market Data 
Discover 
